4.4 Letter

Angiotensin-converting-enzyme inhibitors (ACE inhibitors) and angiotensin II receptor blocker (ARB) use in COVID-19 prevention or treatment: A paradox

Related references

Note: Only part of the references are listed.
Editorial Material Medicine, General & Internal

COVID-19-New Insights on a Rapidly Changing Epidemic

Carlos del Rio et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Editorial Material Virology

Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle

Hongzhou Lu et al.

JOURNAL OF MEDICAL VIROLOGY (2020)

Article Medicine, General & Internal

A Novel Coronavirus from Patients with Pneumonia in China, 2019

Na Zhu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Editorial Material Public, Environmental & Occupational Health

COVID-19: a fast evolving pandemic

Jimmy Whitworth

TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE (2020)

Review Pharmacology & Pharmacy

ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis

A. C. Simoes e Silva et al.

BRITISH JOURNAL OF PHARMACOLOGY (2013)

Article Biochemistry & Molecular Biology

A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury

K Kuba et al.

NATURE MEDICINE (2005)

Article Multidisciplinary Sciences

Angiotensin-converting enzyme 2 protects from severe acute lung failure

Y Imai et al.

NATURE (2005)